NCT00880074 is a Phase 1 clinical trial of Fluorothymidine F-18 in Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00880074?

NCT00880074 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00880074?

Interventions in NCT00880074: Fluorothymidine F-18, Laboratory Biomarker Analysis, Positron Emission Tomography.

What condition does NCT00880074 study?

NCT00880074 studies Malignant Neoplasm.

Is NCT00880074 still recruiting?

NCT00880074 is currently completed. Last updated 26 June 2023.

Last reviewed 2023-06-26 · How we verify

NCT00880074

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

Completed Phase 1 Last updated 26 June 2023

What this trial tests

Phase 1 trial testing Fluorothymidine F-18 in Malignant Neoplasm in 10 participants. Completed in 4 February 2022.

Timeline

9 April 2009

Primary endpoint
4 February 2022

4 February 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	10
Start date	9 April 2009
Primary completion	4 February 2022
Estimated completion	4 February 2022
Sites	1 location across United States

Drugs / interventions tested

Fluorothymidine F-18
Laboratory Biomarker Analysis — full drug profile →
Positron Emission Tomography

Conditions studied

Malignant Neoplasm — all drugs for Malignant Neoplasm →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial studies fluorine F-18 fluorothymidine (FLT)-positron emission tomography (PET) in predicting response to chemotherapy in patients with advanced malignancies. FLT solution can help locate cancer cells inside the body. Diagnostic procedures, such as FLT-PET, may help find tumors and measure a patient's response to treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Fluorothymidine F-18

Trials testing the same drug.

NCT04221438 — Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement · Phase 2 · terminated
NCT03613259 — Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma · EARLY_PHASE1 · withdrawn
NCT03422731 — Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute · EARLY_PHASE1 · recruiting
NCT02392429 — FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia · Phase 2 · active not recruiting
NCT01251874 — Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer · Phase 1 · active not recruiting

Other recruiting trials for Malignant Neoplasm

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00880074 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 26 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00880074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing